These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1074 related articles for article (PubMed ID: 25806911)
1. Herpes zoster vaccine effectiveness and manifestations of herpes zoster and associated pain by vaccination status. Marin M; Yawn BP; Hales CM; Wollan PC; Bialek SR; Zhang J; Kurland MJ; Harpaz R Hum Vaccin Immunother; 2015; 11(5):1157-64. PubMed ID: 25806911 [TBL] [Abstract][Full Text] [Related]
2. Vaccination: a new option to reduce the burden of herpes zoster. Mick G Expert Rev Vaccines; 2010 Mar; 9(3 Suppl):31-5. PubMed ID: 20192716 [TBL] [Abstract][Full Text] [Related]
3. Zoster Vaccine and the Risk of Postherpetic Neuralgia in Patients Who Developed Herpes Zoster Despite Having Received the Zoster Vaccine. Tseng HF; Lewin B; Hales CM; Sy LS; Harpaz R; Bialek S; Luo Y; Jacobsen SJ; Reddy K; Huang PY; Zhang J; Anand S; Bauer EM; Chang J; Tartof SY J Infect Dis; 2015 Oct; 212(8):1222-31. PubMed ID: 26038400 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Pellissier JM; Brisson M; Levin MJ Vaccine; 2007 Nov; 25(49):8326-37. PubMed ID: 17980938 [TBL] [Abstract][Full Text] [Related]
5. Public health impact of herpes zoster vaccination on older adults in Singapore: a modeling study. Oh H; Tan C; Williams C; Giannelos N; Ng C Hum Vaccin Immunother; 2024 Dec; 20(1):2348839. PubMed ID: 38804600 [TBL] [Abstract][Full Text] [Related]
7. Vaccination against herpes zoster in developed countries: state of the evidence. Drolet M; Oxman MN; Levin MJ; Schmader KE; Johnson RW; Patrick D; Mansi JA; Brisson M Hum Vaccin Immunother; 2013 May; 9(5):1177-84. PubMed ID: 23324598 [TBL] [Abstract][Full Text] [Related]
8. Health economic evaluation of vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia in Germany. Ultsch B; Weidemann F; Reinhold T; Siedler A; Krause G; Wichmann O BMC Health Serv Res; 2013 Sep; 13():359. PubMed ID: 24070414 [TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of vaccination of the elderly against herpes zoster in The Netherlands. de Boer PT; Pouwels KB; Cox JM; Hak E; Wilschut JC; Postma MJ Vaccine; 2013 Feb; 31(9):1276-83. PubMed ID: 23306360 [TBL] [Abstract][Full Text] [Related]
10. A retrospective cohort study evaluating the incidence of herpes zoster and postherpetic neuralgia after a live attenuated Oka-strain herpes zoster vaccine in a real-world setting in Japan. Yaegashi M; Matsui H; Yoshida A; Ban H; Miyazaki R; Oda N; Hattori K; Motomura Y; Usami H; Matsushita H Vaccine; 2024 Jan; 42(3):464-470. PubMed ID: 38172019 [TBL] [Abstract][Full Text] [Related]
11. Herpes zoster vaccine: A health economic evaluation for Switzerland. Blank PR; Ademi Z; Lu X; Szucs TD; Schwenkglenks M Hum Vaccin Immunother; 2017 Jul; 13(7):1495-1504. PubMed ID: 28481678 [TBL] [Abstract][Full Text] [Related]
12. Public Health Impact and Cost-Effectiveness of Non-live Adjuvanted Recombinant Zoster Vaccine in Canadian Adults. McGirr A; Van Oorschot D; Widenmaier R; Stokes M; Ganz ML; Jung H; Varghese L; Curran D Appl Health Econ Health Policy; 2019 Oct; 17(5):723-732. PubMed ID: 31250218 [TBL] [Abstract][Full Text] [Related]
13. Herpes Zoster and Postherpetic Neuralgia: a review of the effects of vaccination. Johnson RW Aging Clin Exp Res; 2009 Jun; 21(3):236-43. PubMed ID: 19571648 [TBL] [Abstract][Full Text] [Related]
14. Public health impact model estimating the impact of introducing an adjuvanted recombinant zoster vaccine into the UK universal mass vaccination programme. van Oorschot DAM; Hunjan M; Bracke B; Lorenc S; Curran D; Starkie-Camejo H BMJ Open; 2019 May; 9(5):e025553. PubMed ID: 31061027 [TBL] [Abstract][Full Text] [Related]